Vivani Medical, Inc. VANI
At closeNov 6, 2026, 5:00 PM EST
After hours · Nov 6, 5:00 PM ET
- YTD
- -13.01%
- 1 year
- -27.21%
- Market cap
- 96.52M
- EPS (ttm)
- -0.36
- Shares out
- 59.23M
- Forward P/E
- -2.11
- YTD return
- -13.01%
- 1-year return
- -27.21%
- Volume
- 262.77K
- Avg volume
- 203.73K
- Open
- 1.04
- Previous close
- 1.04
- Day's range
- 1.04 – 1.10
- 52-week range
- 0.938 – 1.60
- Beta
- 3.52
- Analysts
- Buy
- Price target
- 5.50 (+414.0%)
5Y -7.09 (-86.89%)
Key statistics
- Enterprise value
- 74.69M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 2.90
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -14.29M
- Total cash
- 24.92M
- Total debt
- 20.04M
- Return on equity
- -86.10%
- Short % of float
- 2.50%
- 50-day average
- 1.30
- 200-day average
- 1.46
Analyst view
Consensus: buy
- Target (low)
- 3.00
- Target (mean)
- 5.50
- Target (high)
- 8.00
- Strong buy2
- Buy0
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 13, 2024 | Sep 1, 2024 | 0.00 | -0.11 | — | — |
| Aug 13, 2024 | Jun 1, 2024 | 0.00 | -0.10 | — | — |
| May 13, 2024 | Mar 1, 2024 | 0.00 | -0.12 | — | — |
| Mar 26, 2024 | Dec 1, 2023 | 0.00 | -0.12 | — | — |
| Nov 14, 2023 | Sep 1, 2023 | 0.00 | -0.13 | — | — |
| Aug 14, 2023 | Jun 1, 2023 | 0.00 | -0.13 | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 7, 2024 | HC Wainwright & Co. | init | — | Buy |
| Dec 5, 2022 | ThinkEquity | init | — | Buy |
About Vivani Medical, Inc.
Vivani Medical, Inc., a preclinical stage biopharmaceutical company, engages in the development of miniaturized and subdermal implants that treat chronic diseases. The company uses its NanoPortal implant technology to develop and potentially commercialize drug implant candidates in the treatment of chronic disease, medication non-adherence. Its pipeline includes NPM-115, a high-dose exenatide implant candidate is in preclinical stage development for the treatment of chronic weight management in patients with obesity or overweight; NPM-119, an exenatide implant candidate is in preclinical stage development for the treatment of patients with type 2 diabetes; NPM-139, a miniature, subdermal GLP-1 implant in development for chronic weight management; and OKV-119, an exenatide implant is under development for metabolic diseases in cats including for the treatment of obesity and diabetes. The company is headquartered in Alameda, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- vivani.com
News
Vivani Medical Q2 EPS $(0.07) Beats $(0.08) Estimate 
Vivani Medical To Allow Novo Nordisk To Evaluate NPM-139, The Company’s Semaglutide Drug Implant 
ClearOne To Acquire Vivani Medical Subsidiary Cortigent For 12.5M Shares Of CLRO Worth ~$40.4M; ClearOne To File S-1 Seeking To Raise $10M-$15M 
Vivani Medical Receives Approval From Australian Human Research Ethics Committee Bellberry To Initiate SLIM-1, A Phase 1 Clinical Trial Of Semaglutide Implant NPM-139 
Lake Street Initiates Coverage On Vivani Medical with Buy Rating, Announces Price Target of $4 
12 Health Care Stocks Moving In Thursday's Pre-Market Session 
Vivani Medical Q4 EPS $(0.09) Beats $(0.10) Estimate. 
Vivani's Brain Implant Helps Blind Patients See Light And Movement In 6-Year Study - Vivani Medical Q3 EPS $(0.11), Inline
- Vivani Medical Expects To Spin Off Cortigent Unit; Starts Clinical Development Of NPM-139 Semaglutide Implant In Obesity, Chronic Weight Management In 2026
Your note
Sign in to keep a note on VANI — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BOLCK JOACHIM EBERHARD | Beneficial Owner of more than 10% of a Class of Security | Purchase | Jan 2, 2023 | 0 |
| DWYER DONALD | Officer | Purchase | Oct 2, 2024 | 50,000 |
| LARSON ALEXANDRA L.P. | Beneficial Owner of more than 10% of a Class of Security | Stock Award(Grant) | Apr 17, 2023 | 2,166 |
| MAKES BRIGID A | Chief Financial Officer | Purchase | Dec 17, 2023 | 15,000 |
| MENDELSOHN AARON | Director | Purchase | Jun 8, 2023 | 188,170 |
| MENDELSOHN ADAM | Chief Executive Officer | Stock Gift | Feb 7, 2023 | 3,605,020 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Sabby Management, LLC | 3.59% | 2,128,042 | 2.51M | Sep 29, 2024 |
| Tanager Wealth Management LLP | 2.20% | 1,303,000 | 1.54M | Sep 29, 2024 |
| Vanguard Group Inc | 1.63% | 967,398 | 1.14M | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.58% | 342,891 | 404.61K | Sep 29, 2024 |
| Commonwealth Equity Services, LLC | 0.56% | 330,530 | 390.02K | Sep 29, 2024 |
| Monetary Management Group, Inc. | 0.33% | 193,977 | 228.89K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1.07% | 636,702 | 751.31K | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 0.53% | 314,417 | 371.01K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.30% | 175,612 | 207.22K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.09% | 51,787 | 61.11K | Oct 30, 2024 |
| iShares Micro Cap ETF | 0.08% | 47,980 | 56.62K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.07% | 41,496 | 48.97K | Oct 30, 2024 |